🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

122 results for “BEONE MEDICINES AUS PTY LTD” Clear

  1. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    B-cell Malignancies

    phase 3 small molecule active

    1 trial

  2. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  3. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

  4. Zanubrutinib, BGB-11417, BGB-11417, BGB-11417, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, BGB-11417, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    treatment-naive Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  5. Zanubrutinib, Bendamustin Hikma 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, MabThera 100 mg concentrate for solution for infusion, Bendamustin Kabi 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, MabThera 500 mg concentrate for solution for infusion

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  6. zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  7. Atezolizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Liver Cancers

    phase 2 small molecule active

    1 trial

  8. BGB-10188

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    1 trial

  9. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Leukemia

    phase 2 small molecule active

    1 trial

  10. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  11. BGB-11417, POSACONAZOLE, Azacitidine betapharm 25 mg/mL powder for suspension for injection, BGB-11417, BGB-11417, AZACITIDINE

    BEONE MEDICINES AUS PTY LTD

    Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.

    phase 2 small molecule active

    1 trial

  12. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  13. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    previously untreated chronic lymphocytic leukemia (CLL)

    phase 2 small molecule active

    1 trial

  14. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    B-cell Malignancy

    phase 2 small molecule active

    3 trials

  15. BGB-45035

    BEONE MEDICINES AUS PTY LTD

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  16. BGB-A445

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  17. Blinatumomab

    BEONE MEDICINES AUS PTY LTD

    B Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  18. Blinatumomab

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  19. CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    BEONE MEDICINES AUS PTY LTD

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  20. Cyclophosphamide

    BEONE MEDICINES AUS PTY LTD

    Recurrent Transformed Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  21. Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, Zanubrutinib, Mosunetuzumab, Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-16673, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11

    BEONE MEDICINES AUS PTY LTD

    Relapsed or Refractory B-Cell Malignancies

    phase 2 small molecule active

    1 trial

  22. Gimistotug

    BEONE MEDICINES AUS PTY LTD

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  23. Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, BGB-11417, DEXAMETHASONE , Kyprolis 60 mg powder for solution for infusion

    BEONE MEDICINES AUS PTY LTD

    relapsed or refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  24. LBL-007

    BEONE MEDICINES AUS PTY LTD

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources